ClinicalTrials.gg
Drug

Eculizumab clinical trials

Also written Soliris.

studies test it
81
open now
5
in phase 3
30
first study started
2004

How each study uses eculizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the eculizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Mar 2007 · SOLIRIS · BLA 125166 (FDA, Drugs@FDA)
European Union
20 Jun 2007 · Soliris · EMEA/H/C/000791 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Eculizumab
72
Eculizumab (Soliris®)
3
Complement protein C5 inhibitor
2

Brand

Soliris
36
Elizaria®
1

Biosimilars

BCD-148
2
SB12
1
ABP 959
1

Studies by the year they started

81 studies that test it; most in 2009 (8)

Studies that test eculizumab, by start year
YearStudies
20044
20052
20072
20083
20098
20105
20116
20125
20133
20146
20155
20161
20171
20185
20193
20203
20215
20221
20233
20243
20254
20263

Who runs them

Industry 41 · Other 40

Alexion Pharmaceuticals, Inc. (31) · Biocad (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Mayo Clinic (3) · Assistance Publique - Hôpitaux de Paris (3) · Tianjin Medical University General Hospital (2) · Samsung Bioepis Co., Ltd. (2) · Johns Hopkins University (2)

Often tested with

Tested in the same studies.

Ravulizumab (3) · HRS-5965 (1) · Satralizumab (1) · Inebilizumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Eculizumab is the comparator. A study of two new drugs counts under both.

  • 1Crovalimab · Hoffmann-La Roche · next primary completion Apr 2027
  • 1VSA012 · Bisirna Therapeutics (Suzhou) Co., Ltd. · next primary completion Sep 2027
  • 1FXS6837 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · next primary completion May 2028
  • 1NTQ5082 · Nanjing Chia-tai Tianqing Pharmaceutical · next primary completion Nov 2026
  • 1Lanoracopan · Wuhan Createrna Science and Technology Co., Ltd
Reaching primary completion within a year · 2, 1 in phase 3

Studies that test eculizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses eculizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 81

See all 81 studies that test eculizumab →

Given beside what is tested · 9 — eculizumab is usual care or a partner of the new treatment
As the comparator · 9 — what is tested is compared with eculizumab

Codes

What other systems call eculizumab · ClinicalTrials.gg INT004609

  • MeSH (NLM) C481642eculizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) A3ULP0F556ECULIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 591781Confirmed FDA, Wikidata
  • Wikidata Q421617eculizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C48386EculizumabOne source FDA
  • DrugBank DB01257One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.